But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
But BeOne canned its alcestobart deal in May.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
There are questions about vuso-vec’s supporting and confirmatory trials.
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
